Drug Profile
GRI 2
Latest Information Update: 16 Dec 2002
Price :
$50
*
At a glance
- Originator NPS Allelix
- Class
- Mechanism of Action Glycine reuptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal cord injuries
Most Recent Events
- 12 Dec 2002 Discontinued - Preclinical for Spinal cord injuries in Canada (unspecified route)
- 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
- 25 Feb 1998 Preclinical development for Spinal cord injuries in Canada (Unknown route)